Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 21Neoplasms 3Neoplasm Metastasis 3Prostatic Neoplasms, Castration-Resistant 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Small Cell Lung Carcinoma 1Recurrence 1Prostate Adenocarcinoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Follicular 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bulbo-Spinal Atrophy, X-Linked 1Bites and Stings 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

enzalutamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Prostate Cancer × enzalutamide × 30 days × Clear all
NCT07198633 2026-06-02

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Recruiting
212 enrolled
Genitourinary

Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡